Secura Bio
Business Services · Nevada, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1995 Village Center Cir Ste 128, Las Veg...Phone Number
(858) 251-1410Website
www.securabio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
1
About Secura Bio
Secura Bio, Inc specializes in the commercialization of oncology medicines, focusing on transforming the potential of oncology therapies. They offer a high-touch approach through their clinical research and development capabilities, including clinical trials and expanded access programs. Their intended clients include healthcare professionals and patients seeking support in oncology treatment. The company is dedicated to maximizing commercial outcomes and optimizing drug pathways in a competitive marketplace.Explore more
Secura Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Secura Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Secura Bio is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Secura Bio
Secura Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Secura Bio recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check if Secura Bio has recently received funding, and reach out quickly before it becomes old news!
Click to see if Secura Bio had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Secura Bio has new funding data
Product Launch: Get notified when Secura Bio launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Secura Bio
Find 2 more new buyers
Compare Similar Companies to Secura Bio
Compare insights from companies similar to Secura Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Secura Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Secura Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Secura Bio.
Secura Bio financials insights
Gather financial insights about Secura Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$350K
Debt
$70M
Secura Bio Tech Stack
A closer look at the technologies used by Secura Bio
See more technologies
Most Recent Scoops
Project
Contracts
Open Position
Open Position
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Secura Bio News & Media
Secura Bio Expands Chief Financial Officer Will Brown’s Leadership Role to Include Chief Operating Officer
BERKELEY HEIGHTS, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced that Will Brown, currently serving as Chief Financial Officer, has been appointed to the additional role of Chief Operating Officer. In this expanded capacity, Mr. Brown will oversee daily operations, ensuring alignment with the company’s strategic goals, while continuing to lead Secura Bio’s fiSecura Bio Announces Participation in Gilmartin Group’s 2026 Corporate Access Event in San Francisco
BERKELEY HEIGHTS, N.J., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology medicines, today announced that Chip Romp, Chief Executive Officer; Will Brown, Chief Financial Officer; and other members of the company management team will participate in Gilmartin Group’s 2026 Corporate Access event taking place on January 12-14, 2026 in San Francisco, CA.Secura Bio Provides Corporate Update and Highlights Progress in its Phase 3 TERZO Study
Terzo remains on track for an interim data readout in early 2027, based on enrollment to dateSecura Bio Announces NCCN® Duvelisib (COPIKTRA®) Update to Clinical Practice Guidelines in Oncology for Cutaneous T-Cell Lymphoma (CTCL), Including Mycosis Fungoides and Sézary Syndrome
BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced that duvelisib (COPIKTRA®) was added by the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a NCCN Category 2A treatment option for mycosis fungoides / Sézary Syndrome (MFSS).
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Secura Bio
Sign Up For FreeTo access detailed company insights
Secura Bio, Inc specializes in the commercialization of oncology medicines, focusing on transforming the potential of oncology therapies. They offer a high-touch approach through their clinical research and development capabilities, including clinical trials and expanded access programs. Their intended clients include healthcare professionals and p... Read More
